Andecaliximab Disappoints in Advanced Gastric Cancer ...Middle East

Medscape - News
Objective response rates were 50.5% in the ADX arm and 41.1% in the placebo arm, but this did not translate to improved survival. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Andecaliximab Disappoints in Advanced Gastric Cancer )

Apple Storegoogle play

Also on site :

Most viewed in News